Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation
| dc.rights.license | open | en_US |
| dc.contributor.author | BLIN, Patrick | |
| dc.contributor.author | DUREAU-POURNIN, C. | |
| dc.contributor.author | COTTIN, Y. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BENICHOU, Jacques | |
| dc.contributor.author | MISMETTI, P. | |
| dc.contributor.author | ABOUELFATH, A. | |
| dc.contributor.author | LASSALLE, Regis | |
| dc.contributor.author | DROZ, C. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | MOORE, Nicholas | |
| dc.date.accessioned | 2020-05-19T08:32:55Z | |
| dc.date.available | 2020-05-19T08:32:55Z | |
| dc.date.issued | 2019 | |
| dc.identifier.issn | 1365-2125 (Electronic) 0306-5251 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/7635 | |
| dc.description.abstractEn | BACKGROUND: We compared the 1-year safety and effectiveness of dabigatran 110 mg (D110) or 150 mg (D150) to vitamin K antagonists (VKA) in patients with non-valvular atrial fibrillation (NVAF), METHODS: New user cohort study of patients dispensed D110 or D150 vs. VKA in 2013 for NVAF, followed 1 year in the French Systeme National des Donnees de Sante (SNDS, 66 million persons). D110 and D150 users were matched 1:1 with VKA users on sex, age, date of first drug dispensing, and high-dimensional propensity score (hdPS). Hazard ratios (HR [95% confidence intervals]) for stroke and systemic embolism (SSE), major bleeding (MB), and death were computed using Cox proportional hazards or Fine and Gray models during exposure. RESULTS: In 14,442 matched D110 and VKA patients, mean age 79, 49% male, 91% with CHA2 DS2 -VASc >/=2 and 8% with HAS-BLED >3, incidence rates of SSE were 1.9% and 2.6% person-years (HR 0.69 [0.56-0.84]), MB 1.8% and 2.9% (0.62 [0.51-0.76]), death 7.2% and 8.6% (0.84 [0.76-0.94]). In 8,389 matched D150 and VKA patients, mean age 67, 67% male, 65% with CHA2 DS2 -VASC >/= 2; < 5% HAS-BLED > 3, incidence rates were for SSE 1.4% and 1.9% (0.76 [0.56-1.04]), MB 0.6 % and 1.9% (0.30 [0.20-0.46]), death 1.6% and 3.6% (0.46 [0.35-0.59]). Numbers needed to treat to observe one fewer death were 78 for D110, 88 for D150 CONCLUSION: In real life D110 and D150 were at least as effective and safer than VKA. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | PharmacoEpi-Drugs | |
| dc.title.en | Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation | |
| dc.title.alternative | Br J Clin Pharmacol | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1111/bcp.13815 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 30423205 | en_US |
| bordeaux.journal | British Journal of Clinical Pharmacology | en_US |
| bordeaux.page | 432-441 | en_US |
| bordeaux.volume | 85 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - U1219 | en_US |
| bordeaux.issue | 2 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-03209505 | |
| hal.version | 1 | |
| hal.date.transferred | 2021-04-27T09:35:47Z | |
| hal.export | true | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=British%20Journal%20of%20Clinical%20Pharmacology&rft.date=2019&rft.volume=85&rft.issue=2&rft.spage=432-441&rft.epage=432-441&rft.eissn=1365-2125%20(Electronic)%200306-5251%20(Linking)&rft.issn=1365-2125%20(Electronic)%200306-5251%20(Linking)&rft.au=BLIN,%20Patrick&DUREAU-POURNIN,%20C.&COTTIN,%20Y.&BENICHOU,%20Jacques&MISMETTI,%20P.&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||